16106-38-0

Basic information

• Product Name: Benzoyl chloride, 4-amino- (9CI)
• Synonyms: Benzoyl chloride, 4-amino- (9CI);Benzoyl chloride, 4-aMino-;p-Aminobenzoyl chloride
• CAS NO: 16106-38-0
• Molecular Formula: C₇H₆ClNO
• Molecular Weight: 155.58164
• Product Categories: ACIDHALIDE
• Mol File: 16106-38-0.mol
• Article Data: 28

Chemical Properties

• Boiling Point: 158-162℃ (18 Torr)
• Flash Point: 126.1 °C
• Appearance: /
• Density: 1.317g/cm³
• Vapor Pressure: 0.00288mmHg at 25°C
• Refractive Index: 1.605
• PKA: 1.21±0.10(Predicted)
• CAS DataBase Reference: Benzoyl chloride, 4-amino- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 4-amino- (9CI)(16106-38-0)
• EPA Substance Registry System: Benzoyl chloride, 4-amino- (9CI)(16106-38-0)

Safety Data

• Hazardous Substances Data: 16106-38-0(Hazardous Substances Data)

Usage

General Description

Benzoyl chloride, 4-amino- (9CI) is a chemical compound with the molecular formula C7H6ClNO. It is a derivative of benzoyl chloride and contains an amino group at the 4th position of the benzene ring. Benzoyl chloride, 4-amino- (9CI) is primarily used in the production of pharmaceuticals and dyes. It is a reactive compound that is prone to hydrolysis in the presence of water, and can also be used in the synthesis of other organic compounds. Benzoyl chloride, 4-amino- (9CI) is a key intermediate in the production of various pharmaceuticals, including antihistamines and antipsychotic medications, as well as in the manufacturing of dyes and pigments.

InChI:InChI=1/C7H6ClNO/c8-7(10)5-1-3-6(9)4-2-5/h1-4H,9H2

Upstream product

• 150-13-0 4-amino-benzoic acid 
• 7719-09-7 thionyl chloride 
• 122-04-3 4-nitro-benzoyl chloride 

Downstream Products

• 103140-29-0 ethyl (4-aminobenzoyl)cyanoacetate 
• 122595-82-8 O^2'_,O3'_,O5'-tris-(4-amino-benzoyl)-adenosine 
• 21500-76-5 β-methylprocaine 
• 21500-79-8 4-amino-benzoic acid-(2-diethylamino-1-methyl-propyl ester) 
• 21500-81-2 4-amino-benzoic acid-(diethylamino-tert-butyl ester) 
• 21500-77-6 4-amino-benzoic acid-(β-diethylamino-isobutyl ester) 
• 21500-82-3 4-Amino-benzoic acid 2-diethylamino-1,1-dimethyl-propyl ester 
• 21500-80-1 4-Amino-benzoic acid 2-diethylamino-1,2-dimethyl-propyl ester 
• 65057-13-8 5-(4'-Amino-benzoyl)-2-indan-carbonsaeure-methylester 
• 21500-83-4 4-Amino-benzoic acid 2-diethylamino-1,1,2-trimethyl-propyl ester 
• 21500-78-7 α-methylprocaine 
• 90531-50-3 4-Amino-benzoic acid 2-hydroxy-3-isopropylamino-propyl ester 
• 83441-52-5 4-Amino-benzoic acid (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 

Relevant articles and documents

Hydrogenation of nitroaromatics to anilines catalyzed by air-stable arene ruthenium (II)–NNN pincer complexes

A series of air-stable, phosphine-free arene ruthenium (II)–NNN pincer complexes (RuL, RuL1, RuL2 and RuL3) have been synthesized and characterized by spectroscopic and single-crystal X-ray analysis. Further, arene ruthenium (II)–NNN pincer complexes have been used as catalyst for hydrogenation of nitroaromatics into aniline in the presence of NaBH4 at room temperature. The catalytic process suggested highly chemo-selective nitroreduction with wide functional group tolerance.

AROMATIC AMINE COMPOUND, CURING AGENT FOR EPOXY COMPOUND, CURABLE COMPOSITION, CURED PRODUCT, METHOD FOR PRODUCING CURED PRODUCT, AND METHOD FOR PRODUCING AROMATIC AMINE COMPOUND

An aromatic amine compound capable of satisfactorily forming a cured product having exceptional alkali resistance by reaction with an epoxy compound; a curing agent for an epoxy compound, the curing agent including the aromatic amine compound; a curable composition including the curing agent for an epoxy compound; a cured product of the curable composition; a method for producing the cured product; and a method for producing the abovementioned aromatic amine compound. The aromatic amine compound has a structure such that a specific position in a central skeleton comprising a fused ring such as a fluorene ring is substituted with a side-chain group including two aromatic groups linked by a flexible bond such as an amide bond, at least one amino group is bonded to the end of the side-chain group, and the structure has no hydroxyl groups.

2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase

Renewed interest in covalent inhibitors of enzymes implicated in disease states has afforded several agents targeted at protein kinases of relevance to cancers. We now report the design, synthesis and biological evaluation of 6-ethynylpurines that act as covalent inhibitors of Nek2 by capturing a cysteine residue (Cys22) close to the catalytic domain of this protein kinase. Examination of the crystal structure of the non-covalent inhibitor 3-((6-cyclohexylmethoxy-7H-purin-2-yl)amino)benzamide in complex with Nek2 indicated that replacing the alkoxy with an ethynyl group places the terminus of the alkyne close to Cys22 and in a position compatible with the stereoelectronic requirements of a Michael addition. A series of 6-ethynylpurines was prepared and a structure activity relationship (SAR) established for inhibition of Nek2. 6-Ethynyl-N-phenyl-7H-purin-2-amine [IC50 0.15 μM (Nek2)] and 4-((6-ethynyl-7H-purin-2-yl)amino)benzenesulfonamide (IC50 0.14 μM) were selected for determination of the mode of inhibition of Nek2, which was shown to be time-dependent, not reversed by addition of ATP and negated by site directed mutagenesis of Cys22 to alanine. Replacement of the ethynyl group by ethyl or cyano abrogated activity. Variation of substituents on the N-phenyl moiety for 6-ethynylpurines gave further SAR data for Nek2 inhibition. The data showed little correlation of activity with the nature of the substituent, indicating that after sufficient initial competitive binding to Nek2 subsequent covalent modification of Cys22 occurs in all cases. A typical activity profile was that for 2-(3-((6-ethynyl-9H-purin-2-yl)amino)phenyl)acetamide [IC50 0.06 μM (Nek2); GI50 (SKBR3) 2.2 μM] which exhibited >5-10-fold selectivity for Nek2 over other kinases; it also showed > 50% growth inhibition at 10 μM concentration against selected breast and leukaemia cell lines. X-ray crystallographic analysis confirmed that binding of the compound to the Nek2 ATP-binding site resulted in covalent modification of Cys22. Further studies confirmed that 2-(3-((6-ethynyl-9H-purin-2-yl)amino)phenyl)acetamide has the attributes of a drug-like compound with good aqueous solubility, no inhibition of hERG at 25 μM and a good stability profile in human liver microsomes. It is concluded that 6-ethynylpurines are promising agents for cancer treatment by virtue of their selective inhibition of Nek2. This journal is